作者
Matthieu Duchmann, Jean-Baptiste Micol, Nicolas Duployez, Emmanuel Raffoux, Xavier Thomas, Jean-Pierre Marolleau, Thorsten Braun, Lionel Ades, Sylvain Chantepie, Emilie Lemasle, Celine Berthon, Jean-Valere Malfuson, Cecile Pautas, Juliette Lambert, Nicolas Boissel, Karine Celli-Lebras, Denis Caillot, Pascal Turlure, Norbert Vey, Arnaud Pigneux, Christian Recher, Christine Terre, Claude Gardin, Raphael Itzykson, Claude Preudhomme, Herve Dombret, Stephane De Botton
发表日期
2021/5/20
期刊
Blood, The Journal of the American Society of Hematology
卷号
137
期号
20
页码范围
2827-2837
出版商
American Society of Hematology
简介
In patients with isocitrate dehydrogenase (IDH)–mutated acute myeloid leukemia (AML) treated by intensive chemotherapy (IC), prognostic significance of co-occurring genetic alterations and allogeneic hematopoietic stem cell transplantation (HSCT) are of particular interest with the advent of IDH1/2 mutant inhibitors. We retrospectively analyzed 319 patients with newly diagnosed AML (127 with IDH1, 135 with IDH2R140, and 57 with IDH2R172 mutations) treated with IC in 3 Acute Leukemia French Association prospective trials. In each IDH subgroup, we analyzed the prognostic impact of clinical and genetic covariates, and the role of HSCT. In patients with IDH1 mutations, the presence of NPM1 mutations was the only variable predicting improved overall survival (OS) in multivariate analysis (P < .0001). In IDH2R140-mutated AML, normal karyotype (P = .008) and NPM1 mutations (P = .01) predicted better …
学术搜索中的文章
M Duchmann, JB Micol, N Duployez, E Raffoux… - Blood, The Journal of the American Society of …, 2021